TORNA ALLA VERSIONE GRAFICA

INVESTINTUSCANY - Sito ufficiale

INTESTAZIONE GRAFICA (CANALE)

CONTENUTI

Vai al menu di navigazione
| « indietro | stampa pagina

ANGINA PECTORIS: MENARINI IN 68 COUNTRIES WITH AN INNOVATIVE DRUG

The Menarini Group signed an agreement with CV Therapeutics, a biopharmaceutical company in California, granting the exclusive rights to an innovative drug for the treatment of chronic stable angina, in 68 countries. This includes all of Europe and the main countries of Central and South America.

Ranexa (ranolazine) is a drug with an innovative mechanism of action approved by the EMEA (European Medicines Agency) last July and is indicated in the adjunctive symptomatic treatment of patients with chronic stable angina who are not adequately controlled or who have not achieved an adequate response with other antianginal drugs.

Chronic stable angina is a highly debilitating cardiovascular disease associated with coronary artery conditions and characterized by frequent and unpredictable chest pain. Patients affected with this disease have difficulty in carrying out everyday activities and experience a deterioration of the quality of life.
In the five largest European countries (United Kingdom, Germany, France, Spain and Italy), approximately 12 million patients suffer from chronic stable angina.

The drug will be available in Europe during the first half of 2009.
"This agreement is proof of Menarini's focalization on the most innovative therapies and is a strong sign of the vitality of Italian companies in one of the most highly technological sectors representing the future of our country," declared Dr. Alberto Aleotti, President of the Menarini Group.

Menarini's specific know-how in cardiovascular research is a very important added value in consideration of the new scientific acquisitions on the product and of its further development, which Menarini is already working on in its research centers.
"Ranexa is the founder of a new therapeutic class. We believe it is extremely important in responding to the therapeutic necessities that have remained unmet in patients suffering from chronic stable angina," commented Dr. Carlo Alberto Maggi, Director of Research and Development at Menarini.


Florence, September 12, 2008 (www.menarini.com)

 

Docs